ReviewFrontiers in immunology2026
GLI3 in cancer: a context-dependent regulator with diagnostic, prognostic, and therapeutic potential.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malignant tumors remain a major global health burden, creating an urgent need for biomarkers and therapeutic targets that can improve diagnosis, prognostic stratification, and treatment. This review focuses on glioma-associated oncogene family zinc finger 3 (GLI3), a context-dependent transcription factor in the Hedgehog signaling pathway. Main body: We integrated current evidence on GLI3 isoform processing, including the full-length activator GLI3A and the cleaved repressor GLI3R, as well as canonical and non-canonical regulatory mechanisms and the functional consequences of altered GLI3 signaling across diverse tumor types. The analysis revealed that GLI3 exerts both oncogenic and tumor-suppressive effects in a highly context-dependent manner. These effects are governed by the balance between GLI3A and GLI3R, tumor-specific signaling networks, and microenvironmental influences. Dysregulated GLI3 signaling is associated with epithelial-mesenchymal transition, cancer stem cell maintenance, immune remodeling, and therapeutic resistance. Moreover, GLI3 expression and isoform patterns show promise as diagnostic, prognostic, and susceptibility biomarkers. Emerging therapeutic strategies target GLI3 through indirect modulation, direct inhibition, or combination approaches. These findings highlight the potential clinical utility of GLI3. Conclusion: This review identifies GLI3 as a pivotal regulator of tumor biology and highlights its potential as a promising target for precision oncology. Key challenges for future research include the development of isoform-specific detection methods, clarification of non-canonical regulatory mechanisms, and improved translational validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.